MS023 (Medimscience)

MS023 is a preclinical monoclonal antibody developed by Medimscience that targets MT023, a proprietary macrophage-related protein. It is currently under investigation for the treatment of solid tumors and inflammatory bowel disease (IBD). The therapeutic approach involves modulating macrophage activity within the disease environment—either to overcome immunosuppression in the tumor microenvironment or to reduce inflammation in the gut. As a macrophage-targeting agent, MS023 represents a novel immunotherapeutic strategy aimed at addressing conditions with significant unmet medical needs by leveraging the role of the innate immune system in disease progression.

Other names

MT023 monoclonal antibodyMT-023 monoclonal antibodyMT 023 monoclonal antibody